What's in the pipeline for lower functional gastrointestinal disorders in the next 5 years?

Research output: Contribution to journalReview articlepeer-review

2 Scopus citations


The overall objectives of this review are to summarize actionable biomarkers for organic etiology of lower functional gastrointestinal disorders (FGIDs) that lead to individualized treatment for their FGIDs and to assess the pipeline for novel approaches to the management of constipation, diarrhea, and chronic abdominal pain in lower FGIDs. The new approaches to therapy include ion exchangers/transporters for functional constipation (sodium-glucose cotransporter 1, Na_/H_ exchanger 3, and solute carrier family 26 member 3 inhibitors), bile acid modulators for constipation such as ileal bile acid transporter inhibitors and fibroblast growth factor 19 analog for functional constipation, and bile acid sequestrants or farnesoid X receptor agonists for functional diarrhea. Treatment for chronic abdominal pain remains an unmet need in patients with lower FGIDs, and promising novel approaches include delayed-release linaclotide, nonclassical opioid visceral analgesics, and selective cannabinoid receptor agonists. The role of probiotics, fecal microbial transplantation, and possible future microbiome therapies is discussed.

Original languageEnglish (US)
Pages (from-to)G640-G650
JournalAmerican Journal of Physiology - Gastrointestinal and Liver Physiology
Issue number5
StatePublished - Nov 2019


  • Bile acid modulators
  • Bile acid sequestrants
  • Biomarkers
  • Cannabinoid receptor agonists
  • Individualized treatment
  • Ion exchangers/transporters
  • Linaclotide
  • Opioid visceral analgesics

ASJC Scopus subject areas

  • Physiology
  • Hepatology
  • Gastroenterology
  • Physiology (medical)


Dive into the research topics of 'What's in the pipeline for lower functional gastrointestinal disorders in the next 5 years?'. Together they form a unique fingerprint.

Cite this